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Abstract— Enantiomerically pure mono-N-Boc-protected trans-cyclohexane-1,2-diamines are used as organocatalysts for the 
enantioselective conjugate addition of α,α-disubstituted aldehydes to maleimides. Using a single enantiomer of the organocatalyst, both 
enantiomeric forms of the resulting Michael adducts bearing a new quaternary stereocenter are obtained in high yields, only by changing the 
reaction solvent from chloroform (up to 86% ee) to aqueous DMF (up to 84% ee).  
1. Introduction 
The organocatalytic enantioselective Michael addition 
of carbon nucleophiles to maleimides is the most direct 
and easy way of preparing enantioenriched succinimide 
moieties,1 which are present in natural products and some 
clinical drug candidates.2 Moreover, succinimides can be 
transformed into γ-lactams,3 which are privileged 
structural subunits for the design of pharmaceutical agents 
important in the treatment of cancer,4 epilepsy,5 HIV,6 
neurodegenerative disease and depression.7  
Carbon nucleophiles suitable for the enantioselective 
conjugate addition to maleimides can be generated by α-
deprotonation of pro-nucleophiles using chiral 
bifunctional organocatalysts bearing both an acidic 
moiety and a tertiary amine.1 Coordination of the 
maleimide and the enolate generated after deprotonation 
to the chiral organocatalyst leads to an enantioselective 
process. However, when aldehydes are used as pro-
nucleophiles, tertiary amines are not basic enough for the 
efficient generation of an enolate, and these 
organocatalysts cannot be employed. In this case, the 
enantioselective Michael addition reaction can be carried 
out by using amine-bearing organocatalysts suitable to 
form a transient enamine with the reacting aldehyde,8 thus 
creating a chirality-inducing transition state after 
coordination with the maleimide. The first organocatalytic 
Michael addition of aliphatic aldehydes to N-aryl-
maleimides used α,α-phenylprolinol silyl ether as 
organocatalyst, although α,α-disubstituted aldehydes 
resulted in much lower enantioselectivities.9  
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Taking into consideration this enamine-forming 
approach, different bifunctional primary amine-bearing 
organocatalysts have been applied to the enantioselective 
Michael addition of these “difficult” α,α-disubstituted 
aldehydes to maleimides, giving high enantioselections of 
the corresponding succinimides.10 Some examples are the 
primary amine-thioureas 1,10a, 10b  210a, 10b and 3,10e the 
beyerane-containing thiourea 4,10f the primary amine-
guanidine 510h, 10j and even the simple trans-cyclohexa-
1,2-diamine 6.10k  
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When dealing to enantioselective organocatalysis, as 
in any asymmetric catalysis, opposite enantiomeric 
products are typically obtained by using opposite 
enantiomeric organocatalysts. However, switching the 
enantioselectivity of an organocatalyst just by variation of 
the reaction conditions, although potentially very 
interesting, is not an easy matter. Thus, a few examples of 
switching the enantioselectivity of an organocatalyzed 
   
process by changing counteranions of the catalyst,11 
adding bases,12 acids13 or other additives14 or even by 
light irradiation,15 have been reported. In addition, 
examples of changing the enantioselectivity of 
organocatalyzed reactions simply by changing the 
reaction solvent are scarce, and limited to the use in some 
particular cases of some chiral unsupported16a and 
supported16b MacMillan’s imidazolidinones or α,α-
diphenyl-2-pyrrolidinemethanol17 as organocatalysts, as 
well as conformationally flexible peptidic18 and 
guanidine/bisthiourea species.19     
We report in this paper how a change in the solvent in 
the enantioselective addition reaction of the  particularly 
“difficult” α,α-disubstituted aldehydes to maleimides 
allows employing a single enantiomer of N-Boc-
monoprotected trans-cyclohexa-1,2-diamines as organo-
catalysts for the synthesis of both enantiomers of the final 
succinimides.  
 
2. Results and discussion 
The (1S,2S)-cyclohexane-1,2-diamine (6) was chosen as 
chirality source, performing its mono-N-protection with 
the tert-butoxycarbonyl (Boc) group by means of a 
procedure consisting of reaction of 6 with 1 eq of 
hydrogen chloride (2M, Et2O) and subsequent treatment 
with di-tert-butyl carbonate.20  The obtained chiral mono-
Boc-protected diamine 7 was explored as primary amine-
containing organocatalyst for the model enantioselective 
Michael addition of isobutyraldehyde to N-
phenylmaleimide, under different reaction conditions 
(Table 1).  
NH2
NHBoc
7
NH2
NHBoc
ent-7  
Thus, the use of a 20 mol% loading of 7 in toluene as 
solvent at room temperature gave rise to an almost 
quantitative yield of the succinimide (S)-10aa in 67% ee 
(Table 1, entry 1). The absolute configuration was 
determined according to the order of elution of the 
corresponding enantiomers in chiral HPLC (see 
experimental).10j Changing the solvent to hexane gave a 
higher ee of (S)-10aa, whereas the use of ether as solvent 
lowered the enantioselectivity (Table 1, entries 2 and 3). 
When CH2Cl2 and CHCl3 were employed as solvents, 
63% and 75% ee‘s of (S)-10aa, respectively, were 
observed (Table 1, entries 4 and 5).  
However, it resulted surprising that when DMF was 
used as solvent the enantioselectivity of the process 
switched totally, allowing to obtain the opposite (R)-10aa 
in 62% ee (Table 1, entry 6). The use of water as solvent 
increased considerably the reaction rate, affording also 
(R)-10aa almost quantitatively in 2h although in only 
32% ee (Table 1, entry 7). Therefore, we explored the 
possible use of mixtures of DMF/H2O as solvents, 
something that has resuted effective when primery amine-
guanidines have been used as organocatalysts in this 
reaction.10h, 10j Thus, different DMF/H2O v/v ratios were 
assayed (Table 1, entries 8-10), a 2/1 v/v ratio affording 
(R)-10aa in 90% yield and 84% ee (Table 1, entry 9). 
 
Table 1. Screening and optimization of the reaction conditions for the 
enantioswitched Michael addition reaction. 
catalyst
solvent, T
O
H + N
O
O
Ph
8a 9a
N
O
O
Ph
O
H *
10aa
a Isolated yield after flash chromatography.  
b Enantioselectivities and absolute stereochemistry determined by chiral 
HPLC.  
c 1/1, v/v. 
d 2/1, v/v. 
e 4/1, v/v. 
Once the most appropriate solvents for achieving 
opposite enantioselectivities were selected [CHCl3 for 
(S)-10aa and DMF/H2O 2/1 v/v for (R)-10aa], we explore 
lowering the organocatalyst loading. Thus, the amount of 
organocatalyst 7 was diminished to 10 and 5 mol% using 
both solvents (Table 1, entries 11-14, observing the higher 
enantioselections for the (S) and (R) stereoisomers when a 
loading of 10 mol% was used [86% ee for (S)-10aa and 
84% ee for (R)-10aa] (Table 1, entries 11 and 12). Using 
this optimized 10 mol% organocatalyst loading, we 
lowered the reaction temperature down to 0 ºC, but no 
increasing in the stereoselectivity of the reaction was 
observed in any case (Table 1, entries 15 and 16). 
Attempting to achieve opposite enantioselections to 
those obtained using organocatalyst 7, we prepare its 
corresponding enantiomer ent-7 following the same 
procedure but starting from (1R,2R)-cyclohexane-1,2-
diamine. When this mono-N-Boc-protected diamine ent-7 
was used as organocatalyst under the most convenient 
reaction conditions [10 mol% organocatalyst loading, 
room temperature, CHCl3 or DMF/H2O 2/1 v/v as 
solvent], the expected opposite enantioselections than 
when using 7 were observed [(R)-10aa using CHCl3 as 
solvent and (S)-10aa using DMF/H2O 2/1 v/v] (Table 1, 
entries 17 and 18. 
Entry Catalyst  
(mol%) 
Solvent T   
(ºC) 
t  
(h) 
Yield  
(%)a 
ee  
(%)b 
1 7 (20) PhMe 25 20 98 67 (S) 
2 7 (20) Hexane 25 14 85 73 (S) 
3 7 (20) Et2O 25 14 95 32 (S) 
4 7 (20) CH2Cl2 25 20 95 63 (S) 
5 7 (20) CHCl3 25 20 99 75 (S) 
6 7 (20) DMF 25 44 94 62 (R) 
7 7 (20) H2O 25 2 97 32 (R) 
8 7 (20) DMF/H2Oc 25 17 94 70 (R) 
9 7 (20) DMF/H2Od 25 20 90 84 (R) 
10 7 (20) DMF/H2Oe 25 24 88 80 (R) 
11 7 (10) CHCl3 25 20 97 86 (S) 
12 7 (10) DMF/H2Od 25 20 95 84 (R) 
13 7 (5) CHCl3 25 40 95 76 (S) 
14 7 (5) DMF/H2Od 25 40 93 82 (R) 
15 7 (10) CHCl3 0 48 94 70 (S) 
16 7 (10) DMF/H2Od 0 48 91 82 (R) 
17 ent-7 (10) CHCl3 25 20 97 84 (R) 
18 ent-7 (10) DMF/H2Od 25 20 94 83 (S) 
   
 
 
 
 
Table 2. Solvent-dependent enantioswitched Michael addition of aldehydes to maleimides organocatalyzed by mono-Boc-protected 1,2-diamine 7. 
7 (10 mol%)
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Entry Aldehyde Maleimide Solvent t (h) Adduct No Yield (%)a ee (%)b,c 
 R1 No. R2 No.      
1 Me 8a Ph 9a CHCl3 20 (S)-10aa 97 86 
2     DMF/H2O 2/1 20 (R)-10aa 95 84 
3 Me 8a 4-ClC6H4 9b CHCl3 30 (S)-10ab 99 60 
4     DMF/H2O 2/1 30 (R)-10ab 97 74 
5 Me 8a 4-BrC6H4 9c CHCl3 30 (S)-10ac 99 70 
6     DMF/H2O 2/1 30 (R)-10ac 98 70 
7 Me 8a 4-AcOC6H4 9d CHCl3 26 (S)-10ad 92 40 
8     DMF/H2O 2/1 26 (R)-10ad 15 80 
9 Me 8a Me 9e CHCl3 21 (S)-10ae 94 53 
10     DMF/H2O 2/1 21 (R)-10ae 91 68 
11 Me 8a H 9f CHCl3 17 (S)-10af 94 50 
12     DMF/H2O 2/1 17 (R)-10af 88 70 
13 Et 8b Ph 9a CHCl3 48 (S)-10ba 70 55 
14     DMF/H2O 2/1 48 (R)-10ba 93 68 
15 -(CH2)4- 8c Ph 9a CHCl3 30 (S)-10ca 99 49 
16     DMF/H2O 2/1 30 (R)-10ca 96 61 
17 -(CH2)5- 8d Ph 9a CHCl3 48 (S)-10da 96 14 
18     DMF/H2O 2/1 48 (R)-10da 96 35 
a Isolated yield after flash chromatography.  
b Enantioselectivities determined by chiral HPLC (Ref. 22).  
c Absolute configuration assigned by the order of elution of the enantiomers in chiral HPLC (Ref. 23). 
 
 In order to determine if the observed ee for (R)-10aa 
was changing during the process, the model reaction of 
aldehyde 8a and maleimide 9a in the presence of the 
organocatalyst 7 (10 mol%) was carried out in DMF/H2O 
2/1 v/v during reaction times of 4, 8, and 12h. In all cases 
the ee for (R)-10aa was kept in 84%, the same value than 
when the reaction was totally finished. In addition, 
attempting to rule out that the change in the 
enantioselectivity was a consequence of a former 
evolution of the final product, the product (R)-10aa in 
84% ee was combined to organocatalyst 7 (10 mol%) in 
CHCl3 as solvent at room temperature. After 20h stirring, 
the product (R)-10aa was recovered with its 
enantioinduction intact.   
 With the most effective reaction conditions in hand [7 
(10 mol%), CHCl3 for (S)-enantiomer and DMF/H2O 2/1 
v/v for (R)-enantiomer, rt] we explored the extension of 
this organocatalytic solvent-dependent enantioswitching 
methodology to other aldehydes and maleimides (Table 
2).21 As in the case of the model reaction, the absolute 
configuration of the resulting succinimides was assigned 
according to the elution order of their enantiomers in 
chiral HPLC when compared to the literature.22,23  
Thus, when CHCl3 was the solvent of choice, 
isobutyraldehyde reacted with N-phenylmaleimides 
bearing halogens on the phenyl ring, such as a chloro or a 
bromo atom at the 4-position (9b and 9c), and the 
succinimides (S)-10ab and (S)-10ac were obtained in 60 
and 70% ee, respectively (Table 2, entries 3 and 5). 
However, when DMF/H2O 2/1 v/v was the reaction 
solvent, adducts (R)-10ab and (R)-10ac were isolated in 
74 and 70% ee (Table 2, entries 4 and 6). In addition, 
when an acetoxy groups was present onto the phenyl ring 
of the maleimide, as in the case of 9d, the 
enantioselectivities for the corresponding enantiomeric 
succinimides (S)-10ad and (R)-10ad were 40 and 80%, 
depending on the use of CHCl3 or DMF/H2O 2/1 v/v as 
solvents, respectively (Table 2, entries 7 and 8).  
Non-N-arylated maleimides were also employed for 
the conjugate addition with isobutyraldehyde. Thus, N-
methylmaleimide (9e) gave the (S)- and (R)-enantiomer of 
adduct 10ae depending on the use CHCl3 and  DMF/H2O 
2/1 v/v as reaction solvents (53 and 68% ee, respectively) 
(Table 2, entries 9 and 10). In addition, the simple 
maleimide (9f) was also used as Michael acceptor, 
affording (S)-10af (50% ee) using CHCl3 as solvent, and 
(R)-10af (70% ee) when the solvent was DMF/H2O 2/1 
v/v (Table 2, entries 11 and 12). 
Other α,α-disubstituted aldehydes were employed for 
the organocatalyzed Michael addition reaction to N-
phenylmaleimide. Thus, 2-ethylbutanal (8b) afforded 
succinimides (S)-10ba (55% ee) and (R)-10ba (68% ee) 
using CHCl3 and DMF/H2O 2/1 v/v as solvents, 
respectively (Table 2, entries 13 and 14). In addition, 
cyclopentane- (8c) and cyclohexanecarbaldehyde (8d) 
gave almost quantitative amounts of succinimides (S)-
   
10ca and (S)-10da in 49 and 14% ee, respectively, when 
CHCl3 was the reaction solvent, whereas gave the  (R)-
10ca and (R)-10da enantiomers in 61 and 35% ee, 
respectively, using  DMF/H2O 2/1 v/v (Table 2, entries 
15-18). 
 
3. Conclusions 
 It can be concluded that easily prepared N-Boc-
monoprotected chiral trans-cyclohexa-1,2-diamines can 
be used as organocatalysts in the high-yielding 
enantioselective conjugate addition of  α,α-disubstituted 
aldehydes to different maleimides, giving rise to an 
uncommon solvent-dependent enantioswitched reaction. 
Thus, both (S)- or (R)-enantioenriched forms of the 
Michael adducts can be obtained employing a single 
mirror form of the organocatalyst, just by changing the 
reaction solvent from chloroform to aqueous N,N-
dimethylformamide. Further studies devoted to get insight 
into the origin of this solvent-induced stereoselectivity 
switch as well as to extend this methodology to other 
organocatalysts and substrates are now underway.   
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